Terms: = Brain cancer AND MYC, c-Myc, 4609, ENSG00000136997 AND Treatment
294 results:
1. Clinical role of NDRG2-based methylation status on survival pattern of glioblastoma.
Swellam M; Khalifa MK; Nageeb AM; Ezz El-Arab L; El-Mahdy M; El-Bahy K; Sayed Mahmoud M
Int J Immunopathol Pharmacol; 2024; 38():3946320241250294. PubMed ID: 38686946
[TBL] [Abstract] [Full Text] [Related]
2. A therapeutically targetable positive feedback loop between lnc-HLX-2-7, HLX, and myc that promotes group 3 medulloblastoma.
Katsushima K; Joshi K; Yuan M; Romero B; Batish M; Stapleton S; Jallo G; Kolanthai E; Seal S; Saulnier O; Taylor MD; Wechsler-Reya RJ; Eberhart CG; Perera RJ
Cell Rep; 2024 Mar; 43(3):113938. PubMed ID: 38460130
[TBL] [Abstract] [Full Text] [Related]
3. Therapeutic interventions on human breast cancer xenografts promote systemic dissemination of oncogenes.
Raghuram GV; Pal K; Sriram G; Khan A; Joshi R; Jadhav V; Shinde S; Shaikh A; Rane B; Kangne H; Mittra I
PLoS One; 2024; 19(2):e0298042. PubMed ID: 38346047
[TBL] [Abstract] [Full Text] [Related]
4. TRIM25 promotes glioblastoma cell growth and invasion via regulation of the PRMT1/c-myc pathway by targeting the splicing factor NONO.
Chen Y; Xu X; Ding K; Tang T; Cai F; Zhang H; Chen Z; Qi Y; Fu Z; Zhu G; Dou Z; Xu J; Chen G; Wu Q; Ji J; Zhang J
J Exp Clin Cancer Res; 2024 Feb; 43(1):39. PubMed ID: 38303029
[TBL] [Abstract] [Full Text] [Related]
5. The dopamine receptor D1 inhibitor, SKF83566, suppresses GBM stemness and invasion through the DRD1-c-myc-UHRF1 interactions.
Xue Z; Zhang Y; Zhao R; Liu X; Grützmann K; Klink B; Zhang X; Wang S; Zhao W; Sun Y; Han M; Wang X; Hu Y; Liu X; Yang N; Qiu C; Li W; Huang B; Li X; Bjerkvig R; Wang J; Zhou W
J Exp Clin Cancer Res; 2024 Jan; 43(1):25. PubMed ID: 38246990
[TBL] [Abstract] [Full Text] [Related]
6. Marinopyrrole derivative MP1 as a novel anti-cancer agent in group 3 myc-amplified Medulloblastoma.
Coulter DW; Chhonker YS; Kumar D; Kesherwani V; Aldhafiri WN; McIntyre EM; Alexander G; Ray S; Joshi SS; Li R; Murry DJ; Chaturvedi NK
J Exp Clin Cancer Res; 2024 Jan; 43(1):18. PubMed ID: 38200580
[TBL] [Abstract] [Full Text] [Related]
7. Combination drug screen identifies synergistic drug interaction of BCL-XL and class I histone deacetylase inhibitors in myc-amplified medulloblastoma cells.
Zeuner S; Vollmer J; Sigaud R; Oppermann S; Peterziel H; ElHarouni D; Oehme I; Witt O; Milde T; Ecker J
J Neurooncol; 2024 Jan; 166(1):99-112. PubMed ID: 38184819
[TBL] [Abstract] [Full Text] [Related]
8. EXOSC5 maintains cancer stem cell activity in endometrial cancer by regulating the NTN4/integrin β1 signalling axis.
Huang YH; Wang WL; Wang PH; Lee HT; Chang WW
Int J Biol Sci; 2024; 20(1):265-279. PubMed ID: 38164180
[TBL] [Abstract] [Full Text] [Related]
9. Investigation of iso-propylchaetominine anticancer activity on apoptosis, cell cycle and Wnt signaling pathway in different cancer models.
Karamad V; Sogutlu F; Ozkaya FC; Shademan B; Ebrahim W; El-Neketi M; Avci CB
Fitoterapia; 2024 Mar; 173():105789. PubMed ID: 38158162
[TBL] [Abstract] [Full Text] [Related]
10. Combination therapy of niclosamide with gemcitabine inhibited cell proliferation and apoptosis via Wnt/β-catenin/c-myc signaling pathway by inducing β-catenin ubiquitination in pancreatic cancer.
Kang HW; Kim JH; Lee DE; Lee YS; Kim MJ; Kim HS; Fang S; Lee BE; Lee KJ; Yoo J; Kim HJ; Park JS
Cancer Biol Ther; 2023 Dec; 24(1):2272334. PubMed ID: 37917550
[TBL] [Abstract] [Full Text] [Related]
11. Dual PI3K/HDAC Inhibitor BEBT-908 Exhibits Potent Efficacy as Monotherapy for Primary Central Nervous System Lymphoma.
Wang N; Mo Z; Pan L; Zhou M; Ye X; Liu X; Cai X; Qian C; Chen F; Xiong Y; Fan F; Li W
Target Oncol; 2023 Nov; 18(6):941-952. PubMed ID: 37855991
[TBL] [Abstract] [Full Text] [Related]
12. Comparative Analysis of the Embryonal brain Tumors Based on Their Molecular Features.
Shcherbina V; Kovalevska L; Pedachenko E; Malysheva T; Kashuba E
Discov Med; 2023 Oct; 35(178):733-749. PubMed ID: 37811612
[TBL] [Abstract] [Full Text] [Related]
13. Identifying predictors of glioma evolution from longitudinal sequencing.
Mu Q; Chai R; Pang B; Yang Y; Liu H; Zhao Z; Bao Z; Song D; Zhu Z; Yan M; Jiang B; Mo Z; Tang J; Sa JK; Cho HJ; Chang Y; Chan KHY; Loi DSC; Tam SST; Chan AKY; Wu AR; Liu Z; Poon WS; Ng HK; Chan DTM; Iavarone A; Nam DH; Jiang T; Wang J
Sci Transl Med; 2023 Oct; 15(716):eadh4181. PubMed ID: 37792958
[TBL] [Abstract] [Full Text] [Related]
14. Class I HDAC inhibition reduces DNA damage repair capacity of myc-amplified medulloblastoma cells.
Vollmer J; Ecker J; Hielscher T; Valinciute G; Ridinger J; Jamaladdin N; Peterziel H; van Tilburg CM; Oehme I; Witt O; Milde T
J Neurooncol; 2023 Sep; 164(3):617-632. PubMed ID: 37783879
[TBL] [Abstract] [Full Text] [Related]
15. myc up-regulation confers vulnerability to dual inhibition of CDK12 and CDK13 in high-risk Group 3 medulloblastoma.
Pitolli C; Marini A; Guerra M; Pieraccioli M; Marabitti V; Palluzzi F; Giacò L; Tamburrini G; Cecconi F; Nazio F; Sette C; Pagliarini V
J Exp Clin Cancer Res; 2023 Aug; 42(1):214. PubMed ID: 37599362
[TBL] [Abstract] [Full Text] [Related]
16. Pediatric Precision Medicine at the National cancer Center Japan: Prospective Genomic Study of Pediatric Patients with cancer as Part of the TOP-GEAR Project.
Tao K; Yamazaki F; Kubo T; Sunami K; Kumamoto T; Arakawa A; Sugiyama M; Watanabe Y; Nakajima M; Shirakawa N; Tanimura K; Koyama T; Hirata M; Sudo K; Tanabe N; Watanabe T; Yoshida T; Kitami M; Yoshida A; Yatabe Y; Nakano Y; Ohira M; Kamijo T; Nakazawa A; Kato M; Ichimura K; Kohno T; Yamamoto N; Hishiki T; Ichikawa H; Ogawa C
JCO Precis Oncol; 2023 Jul; 7():e2200266. PubMed ID: 37410973
[TBL] [Abstract] [Full Text] [Related]
17. An effective kinase inhibition strategy for metastatic recurrent childhood medulloblastoma.
Adile AA; Bakhshinyan D; Suk Y; Uehling D; Saini M; Aman A; Magolan J; Subapanditha MK; McKenna D; Chokshi C; Savage N; Kameda-Smith MM; Venugopal C; Singh SK
J Neurooncol; 2023 Jul; 163(3):635-645. PubMed ID: 37354357
[TBL] [Abstract] [Full Text] [Related]
18. Optimizing reirradiation for relapsed medulloblastoma: identifying the ideal patient and tumor profiles.
Massimino M; Vennarini S; Buttarelli FR; Antonelli M; Colombo F; Minasi S; Pecori E; Ferroli P; Giussani C; Schiariti M; Schiavello E; Biassoni V; Erbetta A; Chiapparini L; Nigro O; Boschetti L; Gianno F; Miele E; Modena P; De Cecco L; Pollo B; Barretta F
J Neurooncol; 2023 Jul; 163(3):577-586. PubMed ID: 37326761
[TBL] [Abstract] [Full Text] [Related]
19. Celastrol as an emerging anticancer agent: Current status, challenges and therapeutic strategies.
Wang C; Dai S; Zhao X; Zhang Y; Gong L; Fu K; Ma C; Peng C; Li Y
Biomed Pharmacother; 2023 Jul; 163():114882. PubMed ID: 37196541
[TBL] [Abstract] [Full Text] [Related]
20. Molecular characterization of long-term survivors of metastatic medulloblastoma treated with reduced-dose craniospinal irradiation.
Irikura T; Fukuoka K; Nakazawa A; Ichimura K; Kurihara J; Koh K
Childs Nerv Syst; 2023 Sep; 39(9):2505-2507. PubMed ID: 37185696
[TBL] [Abstract] [Full Text] [Related]
[Next]
